Ranbp1 modulates morphogenesis of the craniofacial midline in mouse models of 22q11.2 deletion syndrome
Human Molecular Genetics · 2023
DOI: 10.1093/hmg/ddad030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2023. Verfasst von Elizabeth M Paronett und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, The George Washington School of Medicine and Health Sciences, Washington, DC 20037, USA. Hauptthemen laut MEDLINE: DiGeorge Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Facial dysmorphology is a hallmark of 22q11.2 deletion syndrome (22q11DS). Nearly all affected individuals have facial features characteristic of the syndrome: a vertically long face with broad nasal bridge, narrow palpebral fissures and mild micrognathia, sometimes accompanied by facial skeletal and oropharyngeal anomalies. Despite the frequency of craniofacial dysmorphology due to 22q11.2 deletion, there is still incomplete understanding of the contribution of individual 22q11 genes to craniofacial and oropharyngeal development. We asked whether homozygous or heterozygous loss of function of single 22q11 genes compromises craniofacial and/or oropharyngeal morphogenesis related to these 22q11DS phenotypes. We found that Ranbp1, a 22q11DS gene that mediates nucleocytoplasmic protein trafficking, is a dosage-dependent modulator of craniofacial development. Ranbp1−/− embryos have variably penetrant facial phenotypes, including altered facial morphology and cleft palate. This 22q11DS-related dysmorphology is particularly evident in the midline of the facial skeleton, as evidenced by a robustly quantifiable dysmorphology of the vomer, an unpaired facial midline bone. 22q11DS-related oropharyngeal phenotypes reflect Ranbp1 function in both the cranial neural crest and cranial ectoderm based upon tissue-selective Ranbp1 deletion. Analyses of genetic interaction show that Ranbp1 mutation disrupts BMP signaling-dependent midline gene expression and BMP-mediated craniofacial and cranial skeletal morphogenesis. Finally, midline defects that parallel those in Ranbp1 mutant mice are observed at similar frequencies in the LgDel 22q112DS mouse model. Apparently, Ranbp1 is a modulator of craniofacial development, and in the context of broader 22q11 deletion, Ranbp1 mutant phenotypes mirror key aspects of 22q11DS midline facial anomalies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology, The George Washington School of Medicine and Health Sciences, Washington, DC 20037, USA.
- Center for Neurobiology Research, The Fralin Biomedical Research Institute at Virginia Tech Carilion School of Medicine, Roanoke, VA 24014, USA.
- Department of Biological Sciences, Virginia Tech, Blacksburg, VA 24060, USA.
ORCID-Profile: Thomas M Maynard
Förderung
- NICHD NIH HHS
- National Institute of Child Health and Human Development
Zitieren
APA
Paronett, E. M., Bryan, C. A., Maynard, M. E., Goroff, J. A., Meechan, D. W., LaMantia, A. S., & Maynard, T. M. (2023). Ranbp1 modulates morphogenesis of the craniofacial midline in mouse models of 22q11.2 deletion syndrome. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddad030
Vancouver
Paronett EM, Bryan CA, Maynard ME, Goroff JA, Meechan DW, LaMantia AS, et al. Ranbp1 modulates morphogenesis of the craniofacial midline in mouse models of 22q11.2 deletion syndrome. Human Molecular Genetics. 2023. doi:10.1093/hmg/ddad030
BibTeX
@article{Paronett2023,
author = {Paronett, Elizabeth M and Bryan, Corey A and Maynard, Megan E and Goroff, Julia A and Meechan, Daniel W and LaMantia, Anthony-Samuel and Maynard, Thomas M},
title = {Ranbp1 modulates morphogenesis of the craniofacial midline in mouse models of 22q11.2 deletion syndrome},
journal = {Human Molecular Genetics},
year = {2023},
doi = {10.1093/hmg/ddad030}
}
EUVIMED